Last reviewed · How we verify
MSV treatment
MSV treatment is a Biologic drug developed by Red de Terapia Celular. It is currently in Phase 1 development. Also known as: H-MSV, Human Mesenchymal Stem Cells from Valladolid.
MSV (5-Methoxy-N,N-dimethyltryptamine) is a small molecule modality being studied for various conditions, including coronary artery disease, ischemia, and Alzheimer's disease, primarily through computed tomography angiography. The exact mechanism of MSV treatment is not specified in the provided information, but it is being investigated in clinical trials for its potential therapeutic effects.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MSV treatment |
|---|---|
| Also known as | H-MSV, Human Mesenchymal Stem Cells from Valladolid |
| Sponsor | Red de Terapia Celular |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1 (PHASE4)
- Pain in Fibrous Dysplasia (NA)
- A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body (PHASE1)
- Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient (NA)
- A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers (PHASE1)
- Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (PHASE2)
- The SONImage Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSV treatment CI brief — competitive landscape report
- MSV treatment updates RSS · CI watch RSS
- Red de Terapia Celular portfolio CI
Frequently asked questions about MSV treatment
What is MSV treatment?
Who makes MSV treatment?
Is MSV treatment also known as anything else?
What development phase is MSV treatment in?
Related
- Manufacturer: Red de Terapia Celular — full pipeline
- Also known as: H-MSV, Human Mesenchymal Stem Cells from Valladolid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing